CE 326597

Drug Profile

CE 326597

Alternative Names: CE-326,597

Latest Information Update: 20 Apr 2009

Price : $50

At a glance

  • Originator Pfizer
  • Class Obesity therapies
  • Mechanism of Action Cholecystokinin A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 31 Mar 2009 Discontinued - Phase-II for Obesity in World (PO)
  • 31 Mar 2009 Discontinued - Phase-II for Type-2 diabetes mellitus in World (PO)
  • 31 Mar 2009 Discontinued - Phase-II for Obesity and type 2 diabetes worldwide (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top